Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc
Journal website http://www.thejh.org

Case Report

Volume 9, Number 1-2, April 2020, pages 33-36

Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts

Figures

Figure 1.
Figure 1. Hemoglobin levels: 3 months before treatment, during decitabine plus lenalidomide, 3 years follow-up.
Figure 2.
Figure 2. WBC levels: 3 months before treatment, during decitabine plus lenalidomide, 3 years follow-up. WBC: white blood cell.
Figure 3.
Figure 3. Neutrophil levels: 3 months before treatment, during decitabine plus lenalidomide, 3 years follow-up.
Figure 4.
Figure 4. Platelet levels: 3 months before treatment, during decitabine plus lenalidomide, 3 years follow-up.